Lung Cancer With Copanlisib and Durvalumab

Exclusion Criteria

• •Mixed Non-small cell and small cell histology; known EGFR and/or ALK driver mutations.
• •Treated with sequential chemoradiation therapy.
• •Autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, requiring systemic treatment with immunosuppressant in the past two years.
• •Patients who are receiving any other investigational agents orally or intravenously.
• •Systemic steroid for other purpose exceeding 10 mg prednisone a day except local injection at the discretion of the investigator.
• •Solid organ or bone marrow transplant recipients.
• •History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function.
• •Patients with uncontrolled inter-current illness.
• •Patients with psychiatric illness/social situations that would limit compliance with study requirements and patients with seizure disorder not well controlled.
• •Received live vaccine in the past 4 weeks.
• •Pregnant or breast-feeding/lactating women.
• •Receiving medications prohibited by the study.
• •New York Heart Association Class 3 or above.
• •Myocardial infarction within the last 6 months.
• •Unstable angina.
• •Venous thromboembolism within last 3 months.
• •Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks.
• •Proteinuria of ≥ CTCAE Grade 3 or estimated by urine protein: creatinine ratio \> 3.5
• •Major surgeries within the last 28 days.
• •Any illness or medical conditions that are unstable or could jeopardize the safety of patients and their compliance in the study.